688073 毕得医药
未开盘 10-08 09:30:00
资讯
新帖
简况
股市必读：毕得医药新发布《2026年第三次临时股东会会议资料》
证券之星 · 09-30
股市必读：毕得医药新发布《2026年第三次临时股东会会议资料》
毕得医药（688073）披露拟使用节余及超募资金永久补充流动资金公告，9月29日股价上涨0.5%
证券之星 · 09-29
毕得医药（688073）披露拟使用节余及超募资金永久补充流动资金公告，9月29日股价上涨0.5%
毕得医药科技股份（688073）9月24日主力资金净卖出3459.23万元
证券之星 · 09-25
毕得医药科技股份（688073）9月24日主力资金净卖出3459.23万元
毕得医药科技股份（688073）9月23日主力资金净买入7230.86万元
证券之星 · 09-24
毕得医药科技股份（688073）9月23日主力资金净买入7230.86万元
9月21日毕得医药科技股份涨5.28%，大摩健康产业混合A基金重仓该股
证券之星 · 09-21
9月21日毕得医药科技股份涨5.28%，大摩健康产业混合A基金重仓该股
每周股票复盘：毕得医药科技股份（688073）毕得医药净利增40.73%
证券之星 · 09-20
每周股票复盘：毕得医药科技股份（688073）毕得医药净利增40.73%
9月18日毕得医药科技股份涨5.28%，大摩健康产业混合A基金重仓该股
证券之星 · 09-18
9月18日毕得医药科技股份涨5.28%，大摩健康产业混合A基金重仓该股
9月16日毕得医药涨5.56%，大摩健康产业混合A基金重仓该股
证券之星 · 09-16
9月16日毕得医药涨5.56%，大摩健康产业混合A基金重仓该股
毕得医药：公司董事长戴岚女士本次减持系个人资金安排需要
证券之星 · 09-15
毕得医药：公司董事长戴岚女士本次减持系个人资金安排需要
9月14日毕得医药涨8.07%，大摩健康产业混合A基金重仓该股
证券之星 · 09-14
9月14日毕得医药涨8.07%，大摩健康产业混合A基金重仓该股
每周股票复盘：毕得医药（688073）现695.84万元大宗交易
证券之星 · 09-13
每周股票复盘：毕得医药（688073）现695.84万元大宗交易
9月10日毕得医药跌8.05%，大摩健康产业混合A基金重仓该股
证券之星 · 09-10
9月10日毕得医药跌8.05%，大摩健康产业混合A基金重仓该股
A股异动丨毕得医药大跌超8% 一致行动人股东合计减持2.50%股份
格隆汇 · 09-10
A股异动丨毕得医药大跌超8% 一致行动人股东合计减持2.50%股份
毕得医药(688073.SH)股东拟减持合计不超3%股份
智通财经 · 09-09
毕得医药(688073.SH)股东拟减持合计不超3%股份
毕得医药公告：控股股东及一致行动人拟于10月9日至次年1月8日期间合计减持不超过公司3.0%股份
美股速递 · 09-09
毕得医药公告：控股股东及一致行动人拟于10月9日至次年1月8日期间合计减持不超过公司3.0%股份
毕得医药：控股股东及一致行动人拟合计减持不超3.01%股份
格隆汇 · 09-09
毕得医药：控股股东及一致行动人拟合计减持不超3.01%股份
毕得医药（688073）披露2024年限制性股票激励计划首次及预留授予部分第一个归属期归属结果公告，9月8日股价上涨8.01%
证券之星 · 09-08
毕得医药（688073）披露2024年限制性股票激励计划首次及预留授予部分第一个归属期归属结果公告，9月8日股价上涨8.01%
9月8日毕得医药涨8.01%，大摩健康产业混合A基金重仓该股
证券之星 · 09-08
9月8日毕得医药涨8.01%，大摩健康产业混合A基金重仓该股
每周股票复盘：毕得医药（688073）发生大宗交易成交217.96万元
证券之星 · 09-06
每周股票复盘：毕得医药（688073）发生大宗交易成交217.96万元
每周股票复盘：毕得医药（688073）股东户数增23.07%，净利增40.73%
证券之星 · 08-30
每周股票复盘：毕得医药（688073）股东户数增23.07%，净利增40.73%
加载更多
公司概况
公司名称：
上海毕得医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-10-11
主营业务：
上海毕得医药科技股份有限公司的主营业务是药物分子砌块和科学试剂的研发、设计、生产及销售。公司的主要产品是药物分子砌块、科学试剂。
发行价格：
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":76.6,"timestamp":1791421321000,"preClose":76.6,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":90882900,"shares":90882900,"eps":1.9986,"marketStatus":"未开盘","change":0,"latestTime":"10-08 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":1.9986,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":0,"adr":0,"adjPreClose":76.6,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791423000000,1791430200000],[1791435600000,1791442800000]],"highLimit":84.26,"lowLimit":68.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":90882948,"isCdr":false,"pbRate":3.38,"roa":"--","peRate":38.326829,"roe":"4.95%","epsLYR":1.75,"committee":0,"marketValue":6962000000,"turnoverRate":0,"status":2,"floatMarketCap":6962000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2671244801","title":"股市必读：毕得医药新发布《2026年第三次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671244801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671244801?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:38","pubTimestamp":1790707089,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，毕得医药报收于74.28元，上涨0.5%，换手率4.96%，成交量4.51万手，成交额3.38亿元。当日关注点交易信息汇总：9月29日主力资金净流出134.73万元，游资资金净流出1538.3万元，散户资金净流入1673.02万元。公司公告汇总2026年第三次临时股东会会议资料毕得医药拟将节余募集资金1,268.92万元及剩余超募资金4,234.69万元永久补充流动资金，合计金额占超募资金净额的4.84%，最近12个月内累计使用超募资金补流未超过总额的30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671248938","title":"毕得医药（688073）披露拟使用节余及超募资金永久补充流动资金公告，9月29日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671248938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671248938?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:28","pubTimestamp":1790692097,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，毕得医药报收于74.28元，较前一交易日上涨0.5%，最新总市值为67.51亿元。该股当日开盘71.97元，最高77.99元，最低71.97元，成交额达3.38亿元，换手率为4.96%。近日，毕得医药披露《2026年第三次临时股东会会议资料》。公告显示，公司拟将节余募集资金1,268.92万元及剩余超募资金4,234.69万元永久补充流动资金，合计金额占超募资金净额的4.84%，最近12个月内累计使用超募资金补流未超过总额的30%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900040505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419974","title":"毕得医药科技股份（688073）9月24日主力资金净卖出3459.23万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419974","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419974?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:22","pubTimestamp":1790295733,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，毕得医药科技股份报收于74.55元，下跌7.69%，换手率6.83%，成交量6.21万手，成交额4.75亿元。9月24日的资金流向数据方面，主力资金净流出3459.23万元，占总成交额7.29%，游资资金净流入2493.52万元，占总成交额5.25%，散户资金净流入965.71万元，占总成交额2.03%。毕得医药科技股份主营业务：药物分子砌块和科学试剂的研发、设计、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432759","title":"毕得医药科技股份（688073）9月23日主力资金净买入7230.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669432759?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:15","pubTimestamp":1790208909,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，毕得医药科技股份报收于80.76元，上涨6.12%，换手率7.49%，成交量6.81万手，成交额5.3亿元。近5日资金流向一览见下表：毕得医药科技股份融资融券信息显示，融资方面，当日融资买入6807.01万元，融资偿还4307.04万元，融资净买入2499.96万元，连续3日净买入累计4421.31万元。毕得医药科技股份主营业务：药物分子砌块和科学试剂的研发、设计、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669599611","title":"9月21日毕得医药科技股份涨5.28%，大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669599611","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669599611?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:40","pubTimestamp":1789980043,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日毕得医药科技股份涨5.28%，收盘报71.76元，换手率7.08%，成交量6.43万手，成交额4.57亿元。重仓毕得医药科技股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。大摩健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906429","title":"每周股票复盘：毕得医药科技股份（688073）毕得医药净利增40.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906429","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906429?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:23","pubTimestamp":1789838589,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，毕得医药科技股份报收于68.16元，较上周的55.66元上涨22.46%。本周，毕得医药科技股份9月18日盘中最高价报72.0元。9月14日盘中最低价报54.68元。毕得医药科技股份当前最新总市值61.95亿元，在医疗服务板块市值排名32/51，在两市A股市值排名2711/5220。公司致力于覆盖多样化研发需求，提供定制支持，保障产品质量与及时交付，持续积累品牌认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668492229","title":"9月18日毕得医药科技股份涨5.28%，大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668492229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668492229?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:40","pubTimestamp":1789720834,"startTime":"0","endTime":"0","summary":"证券之星消息，9月18日毕得医药科技股份涨5.28%，收盘报68.16元，换手率7.21%，成交量6.55万手，成交额4.5亿元。重仓毕得医药科技股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。大摩健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800025792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667064456","title":"9月16日毕得医药涨5.56%，大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667064456","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667064456?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:37","pubTimestamp":1789547873,"startTime":"0","endTime":"0","summary":"证券之星消息，9月16日毕得医药涨5.56%，收盘报64.15元，换手率5.52%，成交量5.02万手，成交额3.16亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。大摩健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600026048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667200646","title":"毕得医药：公司董事长戴岚女士本次减持系个人资金安排需要","url":"https://stock-news.laohu8.com/highlight/detail?id=2667200646","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667200646?lang=zh_cn&edition=full","pubTime":"2026-09-15 18:27","pubTimestamp":1789468036,"startTime":"0","endTime":"0","summary":"证券之星消息，毕得医药09月15日在投资者关系平台上答复投资者关心的问题。投资者提问：戴岚董事长，由于你计划减持30万股，动摇了投资者信心，公司股价大跌，创了近期新低，投资者伤痕累累，不知道戴岚董事长减持原因是为了改善生活？公司董事长戴岚女士本次减持系个人资金安排需要。二级市场股价受多重因素影响，公司将持续深耕主业、提升经营质量，以实际行动努力回报投资者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500031495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659213","title":"9月14日毕得医药涨8.07%，大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659213?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:36","pubTimestamp":1789374994,"startTime":"0","endTime":"0","summary":"证券之星消息，9月14日毕得医药涨8.07%，收盘报60.15元，换手率6.12%，成交量5.56万手，成交额3.28亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。大摩健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400021116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507338","title":"每周股票复盘：毕得医药（688073）现695.84万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507338","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507338?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:40","pubTimestamp":1789234822,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，毕得医药报收于55.66元，较上周的58.59元下跌5.0%。交易信息汇总9月8日毕得医药现695.84万元大宗交易。本次减持计划实施前，欣曦管理持有毕得医药3,318,285股，占总股本3.65%；兰旦管理持有2,439,547股，占总股本2.68%；吴波持有748,385股，占总股本0.82%。2026年5月19日披露减持计划，拟在3个月内通过集中竞价或大宗交易方式减持股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566288","title":"9月10日毕得医药跌8.05%，大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666566288?lang=zh_cn&edition=full","pubTime":"2026-09-10 16:37","pubTimestamp":1789029444,"startTime":"0","endTime":"0","summary":"证券之星消息，9月10日毕得医药跌8.05%，收盘报58.58元，换手率6.28%，成交量5.71万手，成交额3.38亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。大摩健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000029175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554033","title":"A股异动丨毕得医药大跌超8% 一致行动人股东合计减持2.50%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554033","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666554033?lang=zh_cn&edition=full","pubTime":"2026-09-10 11:40","pubTimestamp":1789011632,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159982","688073","BK0216","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539605","title":"毕得医药(688073.SH)股东拟减持合计不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539605","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666539605?lang=zh_cn&edition=full","pubTime":"2026-09-09 22:31","pubTimestamp":1788964282,"startTime":"0","endTime":"0","summary":"智通财经APP讯，毕得医药(688073.SH)发布公告，因自身资金需求，戴岚女士、戴龙先生、南煦投资、蓝昀万驰计划根据市场情况，于本减持计划披露之日起15个交易日后的3个月内通过集中竞价、大宗交易方式减持合计不超3%股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"毕得医药(688073.SH)股东拟减持合计不超3%股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195789195","title":"毕得医药公告：控股股东及一致行动人拟于10月9日至次年1月8日期间合计减持不超过公司3.0%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1195789195","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195789195?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:09","pubTimestamp":1788959349,"startTime":"0","endTime":"0","summary":"毕得医药今日披露，公司控股股东及其一致行动人已制定减持计划。根据公告内容，这些股东预计在10月9日至1月8日的时间窗口内，合计减持公司股份比例最高可达3.0%。此举或将对市场情绪产生一定影响，投资者需密切关注后续动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553551","title":"毕得医药：控股股东及一致行动人拟合计减持不超3.01%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553551","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666553551?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:06","pubTimestamp":1788959180,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329402","title":"毕得医药（688073）披露2024年限制性股票激励计划首次及预留授予部分第一个归属期归属结果公告，9月8日股价上涨8.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329402","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665329402?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:53","pubTimestamp":1788861191,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，毕得医药报收于64.2元，较前一交易日上涨8.01%，最新总市值为58.35亿元。近日，上海毕得医药科技股份有限公司发布《关于2024年限制性股票激励计划首次授予及预留授予部分第一个归属期归属结果的公告》。公告显示，公司已完成2024年限制性股票激励计划首次授予及预留授予部分第一个归属期的股份登记，本次归属股票数量为111.2012万股，来源为公司从二级市场回购的A股普通股股票，归属对象共58名。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800027756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325117","title":"9月8日毕得医药涨8.01%，大摩健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665325117?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:39","pubTimestamp":1788856743,"startTime":"0","endTime":"0","summary":"证券之星消息，9月8日毕得医药涨8.01%，收盘报64.2元，换手率8.57%，成交量7.79万手，成交额4.82亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为摩根士丹利基金的大摩健康产业混合A。大摩健康产业混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800026112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665178365","title":"每周股票复盘：毕得医药（688073）发生大宗交易成交217.96万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665178365","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665178365?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:04","pubTimestamp":1788631454,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，毕得医药（688073）报收于58.59元，较上周的61.44元下跌4.64%。本周，毕得医药9月2日盘中最高价报61.8元。9月4日盘中最低价报58.03元。毕得医药当前最新总市值53.25亿元，在医疗服务板块市值排名32/51，在两市A股市值排名3046/5214。本周关注点交易信息汇总：9月4日毕得医药发生1笔大宗交易，成交金额217.96万元交易信息汇总9月4日毕得医药发生1笔大宗交易，成交金额217.96万元以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663801053","title":"每周股票复盘：毕得医药（688073）股东户数增23.07%，净利增40.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663801053","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663801053?lang=zh_cn&edition=full","pubTime":"2026-08-30 01:55","pubTimestamp":1788026112,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，毕得医药报收于61.44元，较上周的71.6元下跌14.19%。业绩披露要点：归母净利润1.03亿元，同比上升40.73%。股本股东变化截至2026年6月30日，公司股东户数为6060.0户，较3月31日增加1136.0户，增幅23.07%。户均持股数量由1.85万股下降至1.5万股，户均持股市值为80.71万元。第二季度单季主营收入3.6亿元，同比上升8.58%；单季归母净利润5647.49万元，同比上升32.22%；单季扣非净利润4367.76万元，同比上升40.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791421351942,"stockEarnings":[{"period":"1week","weight":-0.0515},{"period":"1month","weight":0.2665},{"period":"3month","weight":0.4588},{"period":"6month","weight":0.3365},{"period":"1year","weight":0.0199},{"period":"ytd","weight":0.2848}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"6060人(较上一季度增加23.07%)","perCapita":"14997股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是药物分子砌块和科学试剂的研发、设计、生产及销售。公司的主要产品是药物分子砌块、科学试剂。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}